Last reviewed · How we verify
NCT03556748
WB-EMS and Nutrition in Patients With Hematological Malignancies
NA trial testing whole-body electromyostimulation in Hematologic Diseases in 40 participants. Status unknown.
31 October 2019
Quick facts
| Lead sponsor | University of Erlangen-Nürnberg Medical School |
|---|---|
| Phase | NA |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 40 |
| Start date | 1 November 2017 |
| Primary completion | 31 October 2019 |
| Estimated completion | 31 October 2019 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- whole-body electromyostimulation
Conditions studied
- Hematologic Diseases — all drugs for Hematologic Diseases →
- Cachexia; Cancer — all drugs for Cachexia; Cancer →
- Leukemia — all drugs for Leukemia →
- Myeloma — all drugs for Myeloma →
Sponsor
University of Erlangen-Nürnberg Medical School
Who can join
18 and older, any sex, with Hematologic Diseases or Cachexia; Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study evaluates the effects of a whole-body electromyostimulation (WB-EMS) training combined with individualized nutritional support on skeletal muscle mass, body composition, muscle strength/function, quality of life, fatigue, pain and gastrointestinal symptoms in patients with hematological malignancies 4-6 weeks before and 4-6 weeks after undergoing stem cell Transplantation. Within this context, this study also investigates the effect of the nutrition and exercise intervention on the period of hospitalization, period of White blood cell recovery and frequency and severity of complications (mucositis, Graft-versus-Host-Disease, infections) after stem cell Transplantation as consequences of the therapeutic immune Suppression.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT03556748
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hematologic Diseases
Currently open trials in the same condition.
- NCT07257640 — IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic Leukemia · Phase 1 · recruiting
- NCT06487247 — HEME Home Transfusion Program · NA · recruiting
- NCT05414045 — Autologous Testicular Tissue Transplantation · NA · recruiting
- NCT06613425 — Clinical Study of Combined Platelet Transfusion · Phase 4 · recruiting
- NCT06271252 — A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study · Phase 1 · recruiting
Other University of Erlangen-Nürnberg Medical School trials
Trials by the same sponsor.
- NCT06969820 — Establishment and Evaluation of Standardized Clinical, Biological and Imaging Parameters to Assess the Response of LDRT · not yet recruiting
- NCT07406191 — WB-EMS Effects on Cardiometabolic Risk Factors · NA · recruiting
- NCT07352540 — Single vs Triple Hyaluronic Acid in Knee Osteoarthritis · Phase 2, PHASE3 · not yet recruiting
- NCT07313878 — Evaluation of Acute and Chronic Nephrotoxicity in Acute Lymphatic Leukemia Patients Using Ultrasound Localization Micros · NA · recruiting
- NCT07121985 — Multispectral Optoacoustic Imaging for the Detection of Inflammation and Damage of Peripheral Nerves in Guillain-Barré S · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03556748 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Erlangen-Nürnberg Medical School
- Last refreshed: 14 June 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03556748.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing